Composite hemangioendothelioma of the spleen with multiple metastases: CT findings and review of the literature

Weiwei Li, MDa, Pan Liang, PhDa, Hui Ping Zhao, MDa, Yanxing Zhang, BDb, Yi Yang Liu, MDa, Jianbo Gao, PhDa,*

Abstract
Composite hemangioendothelioma (CHE) is a rare vascular neoplasm of intermediate malignant potential. Only 52 cases have been reported in the English literature, and one case previously reported occurred in the spleen. The purpose of our study was to report a 65-year-old man diagnosed as CHE primary arising from the spleen with multiple metastases.

Clinical and imaging features, laboratory tests, and pathological results about CHE were described in detail in this study. The patient presented with multiple lesions in bilateral lungs and spleen that had been incidentally detected by computed tomography (CT). Except for thrombocytopenia, other laboratory tests were not significant. The CT scan of the abdomen revealed multiple round-like and irregularly mixed density masses with unclear borders in enlarged spleen. And contrast enhancement showed mild heterogeneous enhancement. CT scan also showed widespread liver, ribs, lungs, and vertebral bodies metastases. This diagnosis was confirmed by histopathological examination. The patient underwent splenectomy and still survives with tumors after six months followed-up.

Due to the lack of specificity of clinical features and laboratory tests, it is necessary to combine imaging features and pathological findings to make a correct diagnosis.

Keywords: composite hemangioendothelioma, hemangioendothelioma, spleen, computed tomography

1. Introduction
Hemangioendothelioma (HE) is a term used to name those borderline vascular neoplasms whose clinical behaviors are between the benign hemangiomas and malignant angiosarcoma.

HE includes various tumors with different malignant potentials. The members of the family of HE are intralymphatic angioendothelioma (also known as Dabska tumor), retiform HE, kaposiform HE, epithelioid HE, pseudomyogenic HE (also known as epithelioid sarcoma-like HE), and composite HE. Classified as an intermediate malignancy, CHE, is a rare tumor initially described by Nayler et al. in 2000. CHE mainly occurs in the extremities, followed by the head and neck, with the liver, spleen, and kidney are rarely reported. Most of the patients present with single or multiple purple to red papules or nodules. Treatment options include surgery, chemotherapy and radiotherapy, with total removal of the tumor is mainly implemented. Patients with CHE rarely developed metastases, but local recurrence was not uncommon. The gold standard for diagnosis is pathology, but the preoperative diagnosis is very difficult since there are no special clinical manifestations or laboratory tests. Imaging techniques like X-ray examination, computed tomography (CT), magnetic resonance imaging (MRI), and gallium scintigraphy have been used in the diagnosis of CHE. However, the literature review on imaging features has not been reported to date. In order to give radiologist a better understanding of this disease, we report a rare case of primary CHE of the spleen with multiple distant metastases and review the relevant literature.

2. Methods
A case of asymptomatic CHE originating from the spleen with multiple distant metastases was presented. We searched for
“composite hemangioendothelioma” in PubMed and the Web of Science. A total of 110 studies that may be eligible were initially identified. 28 articles in English were included in the study with 52 patients available after exclusion of duplicate articles, abstracts, and non-relevant literature and the clinical features, imaging findings, and pathological results were summarized and discussed.

3. Results

3.1. Case report

On November 4, 2019, a 65-year-old man presented at our hospital for further treatment of multiple lesions in bilateral lungs and spleen that had been incidentally detected by CT. However, the patient had no related symptoms, such as abdominal tenderness, abdominal distension, and coughing. Physical examination suggested that the spleen was 5 cm below the costal margin. The results of laboratory examination were unremarkable except for the decrease in platelet count (62 × 10^9/L, normal 125–350). Ultrasonography (US) showed a heterogeneous mass measuring 130 mm × 88 mm in the enlarged spleen. The boundary of the mass was poorly circumscribed, and strong echo spots could be detected. Blood flow signals were found inside the mass using Color Doppler flow imaging. Contrast-enhanced CT of the abdomen revealed multiple round-like and irregular mixed density masses in the enlarged spleen (Fig. 1B C). In addition, massive and cloud-like calcifications could also be observed in the lesions (Fig. 1A). The largest mass was measured at 152 × 85 × 132 mm^3. In the venous phase, the boundaries were well-defined than arterial phase and pre-enhanced phase because the splenic parenchyma showed obviously homogeneous enhancement, while these masses were slightly heterogeneous enhanced or not enhanced suggesting necrosis existed. The left kidney was pushed to the other side of the spleen and deformed (Fig. 1C). Furthermore, the liver was detected with multiple spotty lesions in different sizes of low density, which were slightly enhanced after the injection of contrast materials. CT scan of the chest showed high-density nodular shadows with multiple blurred edges in both lungs (Fig. 2A). The largest of them measured 2.2 × 1.6 cm. The bone window showed local destruction of the third rib on the left, with increased density and expansive growth, pushing the adjacent lung tissue (Fig. 2B). CT scans depict the expansive growth of the fifth rib with osteoblastic changes. Also, the density of the thoracic spine, lumbar spine, and pelvis were abnormal. Multiple dot-like stone shadows could be seen at the bottom of the gallbladder. Single-photon emission computed tomography (SPECT) was subsequently performed suggesting multiple bone metastases with intense pathological radionuclide uptake in right scapula, left third rib, right fifth anterior rib, multiple vertebral bodies, sacrum, right hip joint, and left upper abdomen.

Fine-needle aspiration cytology of the splenic mass was performed under CT guidance, and revealed an angiogenic tumor, tending to benign or intermediate malignant lesions. Immunohistochemical results exhibited that the CD31, CD34, F-VIII, FLI-1, and ERG were positive in tumor cells. In addition, Ki67 was observed to be positive in 20% of the tumor cells. However, it showed negative results for AE1/AE3 and TFE-3. To avoid the risk of tumor rupture and thrombocytopenia, splenectomy was performed. The postoperative pathological examination confirmed the diagnosis of CHE, indicating that the grayish-white or grayish-yellow tumor in the cut surface of the resected specimen was medium-hard and that multiple grayish-white or grayish red nodules with a diameter of 7 to 90 mm were observed. The histological findings displayed that the lesion was composed of hemangio-meta-like, epithelioid HE, and papillary intralymphatic HE (Fig. 3A and B). Based on the combination of...
immunophenotype and molecular detection results, the lesion was consistent with CHE.

4. Discussion

CHE is a very rare tumor and only 52 cases have been reported in the English literature so far. The clinical features of these patients are mentioned in Table 1. Of the 52 previously reported cases, the age of onset is from birth to 78 years, with an average age of 42.5 years. Patients with CHE showed a sex predilection of females and sites predilection of the extremities (27/52), with most metastasis, SPECT is recommended.

Characterized by low-grade malignancy, CHE tends to recur with infrequent metastasize, and some cases of successful treatment have been reported.[3,4,12] CHE has a better prognosis than angiosarcoma. To date, only one patient has died of metastatic disease in the reported cases. Therefore, it is important to differentiate CHE from other clinically aggressive angiosarcomas preoperatively. On MRI, relative to the normal splenic parenchyma, these lesions appear as nodular hypointense on both T1WI and T2WI. Large masses with subacute hemorrhage and tumor necrosis may increase the signal intensity on both T1WI and T2WI.[31,32] One or more heterogeneous complex masses of the enlarged spleen are the most common CT findings. Calcification can occasionally be seen in malignant tumors, but it may be more common in CHE. Most of the angiosarcomas present heterogeneous enhancement. Some tumors also show peripheral enhancement, with areas of decreased attenuation

in our case had no clinical symptoms and laboratory tests only showed a reduction in platelet count.

Owing to the lack of specific clinical symptoms and laboratory tests, it is difficult to diagnose a CHE, a needle biopsy or pathological examination is required in patients. However, US, MRI, and CT can help detect masses and differentiate benign form malignant masses. US is used for screening splenic diseases because of its safety, strong discrimination against soft tissues, flexibility, and low cost. However, US is limited in identifying benign and malignant masses, describing the overall appearance of the mass, and diagnosing distant metastases. In addition, the diagnostic accuracy is closely related to the doctor’s operation. Therefore, the diagnosis of CHE needs CT or/and MRI support. MRI revealed single or multiple heterogeneous lesions, which showed slightly high or high signal intensity on T2-weighted images (T2WI) and low to intermediate signal intensity on T1-weighted images (T1WI).[9,17,22,27–30] After the injection of contrast medium, lesions showed moderate or strong heterogeneous enhancement on T1WI, with rare edge enhancement. Several cases have been reported that soft tissue with the lobulated surface was observed on MRI[22,27,28] Tsai et al suggested that MRI revealed unclear plantar lesions, with low dermal/subcutaneous signal intensity and moderate heterogeneity enhancement after gadolinium injection on T1WI.[22] In another case reported by them, the lobulated tumor in the left pyriform sinus showed an intermediate signal intensity on T1WI, and slightly high signal intensity on T2WI, which was significantly enhanced. MRI can clearly depict muscle and soft tissue lesions, but it is not as good as CT for bone invasion and lymph node metastasis. CT revealed one or more heterogeneous and contrast-enhanced masses, with or without lobulation, lymphadenopathy, calcification.[4,6,7,10,12,22,26,28,30] CT of a CHE arising from the spleen showed a large protruding cystic mass in the spleen with multiple liver nodules and supraclavicular lymphadenopathy, which was reported by Yoda et al.[7] In our case, CT displayed multiple lobulated lightly enhanced or unenhanced masses of the spleen with massive calcifications. In addition, multiple metastases of the liver, ribs, lungs, and vertebral bodies were detected. These tumors were also confirmed by SPECT showing strong pathological radioactive tracer concentration in the right scapula, left third rib, right fifth anterior rib, multiple vertebrae, sacrum, right hip, and left upper abdomen. However, the liver display result was inconsistent with the CT display result, probably because the lesion was too small and the SPECT resolution was low. When CT shows bone metastasis, SPECT is recommended.

Characterized by low-grade malignancy, CHE tends to recur with infrequent metastasize, and some cases of successful treatment have been reported.[3,4,12] CHE has a better prognosis than angiosarcoma. To date, only one patient has died of metastatic disease in the reported cases. Therefore, it is important to differentiate CHE from other clinically aggressive angiosarcomas preoperatively. On MRI, relative to the normal splenic parenchyma, these lesions appear as nodular hypointense on both T1WI and T2WI. Large masses with subacute hemorrhage and tumor necrosis may increase the signal intensity on both T1WI and T2WI.[31,32] One or more heterogeneous complex masses of the enlarged spleen are the most common CT findings. Calcification can occasionally be seen in malignant tumors, but it may be more common in CHE. Most of the angiosarcomas present heterogeneous enhancement. Some tumors also show peripheral enhancement, with areas of decreased attenuation

Figure 2. Axial: Chest CT scan shows a high-density nodule with spiculate boundary (arrow) (A). The bone window confirms the osteogenic changes of the third rib on the left side and the adjacent lung tissue being pushed (arrow) (B).
suggesting necrosis or bleeding. The most common metastatic site is the liver (60%), other metastatic sites include lungs, bone, bone marrow, and lymphatic system. The metastatic sites of CHE are similar to angiosarcoma. CHE that occurs in the spleen may have a potential tendency to metastasize than CHE that occurs in the superficial area because there are no clinical symptoms or the symptoms appear later. It is difficult to distinguish CHE and angiosarcoma based on image features, so it is necessary to combine clinical manifestations, laboratory examinations, and histopathological examination.

Histopathologically, CHE is characterized by a complex admixture of benign, intermediate, and malignant vascular components that occur in the deep and subcutaneous layers of the dermis, with infiltrative margins. Based on the previous studies, the most frequent histologic pattern observed in CHE is retiform HE, which is composed of long, arborizing blood vessels in a pattern resembling rete testis. Other common components including spindle cell haemangiomas (large endothelial cells with vacuolated cytoplasm with pseudolipoblastic) and epithelioid HE that typically demonstrates infiltrative chains, cords, and/or nests of epithelioid endothelial cells with lightly eosinophilic cytoplasm have also been seen in some reports. Besides, some benign components are also visible in the areas including cavernous hemangioma and arteriovenous malformations, as shown in some studies. Immunohistology is characterized by the positive expression of CD31, CD34, and von Willebrand factor in the tumors.

Extensive resection treatment beyond the clinical scope is recommended for the treatment of CHE. Amputation of the

| Variable                  | N   |
|---------------------------|-----|
| Gender                    |     |
| Male                      | 22  |
| Female                    | 30  |
| Age, y                    |     |
| Mean                      | 42.5 ± 2.5 |
| Range                     | 0-78 |
| Site                      |     |
| Extremities, hip           | 27  |
| Head, neck                | 13  |
| Back                      | 2   |
| Mediastium                | 1   |
| Manubrium Sterni          | 1   |
| Pulmonary vein            | 1   |
| Liver/Spleen/Kidney       | 2/1/1 |
| Periaortic                | 1   |
| Vertebral                 | 1   |
| Paraspinal region         | 1   |
| Treatment                 |     |
| Surgery                   | 35  |
| Surgery; chemotherapy     | 3   |
| Radiation/Surgery&Radiation | 2/1 |
| Not available             | 11  |
| follow-up                 |     |
| NSR (3 month-7years)      | 24  |
| LR/LR& Met                | 6/4/4 |
| Not available             | 14  |

LR = local recurrence, NSR = no sign of recurrence, Met = metastasis.
## Table 2
Details of clinical and treatment in patients with CHE reported in the English literature.

| Author                | Year | Sex/Age | Site                  | Size (mm) | Preoperative duration | Treatment       | Outcome                  |
|-----------------------|------|---------|-----------------------|-----------|-----------------------|-----------------|--------------------------|
| Nayler et al[3]       | 2000 | M/42    | Foot                  | 60        | 12 yr                 | Surgery         | NSR after 1 yr           |
|                       |      | F/27    | Foot                  | 7–20      | Several months        | Surgery         | LR                       |
|                       |      | M/21    | Finger                | NA        | Several months        | Surgery         | NSR after 13 yr          |
|                       |      | M/44    | Finger                | 10        | Several years         | Surgery         | NSR after 2 yr           |
|                       |      | M/70    | Tongue                | NA        | NA                    | Surgery         | LR, Met submandibular node and thigh |
|                       |      | F/31    | Foot                  | 10        | 2 yr                  | Surgery         | NA                      |
|                       |      | F/71    | Foot                  | 30–40     | 6 yr                  | Surgery         | NA                      |
|                       |      | M/35    | Hand                  | 30        | Several years         | Surgery         | LR                      |
| Reis-Filho et al[4]   | 2002 | F/23    | Forearm, hand         | 130       | Since infancy         | Surgery         | NSR after 7 yr           |
| Sapunar et al[5]      | 2003 | F/43    | Toe                   | NA        | NA                    | Surgery         | NA                      |
| Biagioli et al[18]    | 2005 | F/46    | Toe                   | 20        | 3 yr                  | Surgery         | LR                      |
| Tronnier et al[11]    | 2006 | F/73    | Toe                   | 31        | 10 yr                 | Surgery         | LR                      |
| Fukunaga et al[6]     | 2007 | M/44    | Foot                  | 10        | Since birth           | Partial excision| AWD                     |
|                       |      | M/44    | Mandibular vestibule  | 13        | Several months        | Surgery         | NSR after 13 months      |
|                       |      | F/75    | Thigh                 | 35        | 10 yr                 | Surgery         | LR                      |
|                       |      | F/37    | Arm, axilla, finger, thigh | 40      | Since childhood        | Partial excision| NA                     |
|                       |      | F/22    | Foot                  | 30        | 3 yr                  | Partial excision| NA                     |
| Fasolis et al[12]     | 2008 | M/38    | Oral cavity           | 25        | NA                    | Surgery         | NSR after 3 yr           |
| Requena et al[19]     | 2008 | M/60    | Leg, Foot             | 15        | Several years         | Surgery         | LR, Met to inguinal lymph node |
| Tejera-Vaquero et al[15] | 2008 | F/23    | Back                  | 30        | 2 yr                  | Surgery         | NSR after 30 months      |
| Utas et al[20]        | 2008 | F/62    | Forearm, hand         | 90        | NA                    | Chemotherapy; surgery | NA                     |
| Aydingöz et al[21]    | 2009 | F/48    | Thigh                 | 15        | Several years         | Surgery         | LR, Met to inguinal lymph node |
| Cakir et al[16]       | 2009 | F/50    | Mediastinum           | 6         | 2 mo                  | Surgery         | NSR after 13 mo          |
| Cobianchi et al[17]   | 2009 | F/47    | Liver                 | 90        | NA                    | Surgery         | NSR after 24 mo          |
| Tsai et al[22]        | 2011 | F/23    | Foot                  | 40        | NA                    | Surgery         | NSR after 7 mo           |
|                       |      | F/15    | Hypopharynx           | 32        | Several months        | Surgery         | NSR after 18 mo          |
|                       |      | F/49    | Hypopharynx           | 24        | Several months        | Surgery         | NSR after 10 mo          |
|                       |      | M/8     | Elbow                 | 16        | 18 mo                 | Surgery         | NSR after 48 mo          |
| Chen et al[23]        | 2012 | F/46    | Neck                  | 48        | 4 yr                  | Surgery         | NA                      |
| Yoda et al[24]        | 2012 | F/67    | Spleen                | 48        | 4 mo                  | Surgery; chemotherapy | Met to liver and supraclavicular lymphadenopathy |
| Liu et al[25]         | 2013 | F/24    | Scalp                 | 15        | Several months        | Surgery         | NSR after 1 yr           |
| Tateishi et al[26]    | 2013 | F/34    | Nose                  | 8         | 7 mo                  | Electron beam   | NSR after 9 mo           |
| Zhang et al[10]       | 2013 | F/32    | Kidney                | 26        | 1 wk                  | Surgery         | NSR after 11 mo          |
| Dong et al[17]        | 2014 | M/56    | Manubrium Sterni     | 2         | 2 yr                  | Surgery         | NA                      |
| Mahmoudizad et al[26] | 2014 | M/68    | Scalp, neck           | 5–63      | 10 mo                 | Radiation       | NA                      |
| Stojic et al[9]       | 2014 | M/58    | Hip                   | 30        | Several years         | Surgery         | NSR after 3 mo           |
| Leen et al[27]        | 2015 | M/43    | Submandibula-r area   | 22        | 3 mo                  | Surgery         | NSR after 8 mo           |
| Bhat et al[30]        | 2016 | M/31    | Back                  | 15        | 1 yr                  | Surgery         | NSR after 5 mo           |
| Perry et al[14]       | 2017 | M/47    | Wrist                 | 77        | NA                    | Surgery         | Met to liver, lung, humerus |
|                       |      | F/48    | Ankle                 | NA        | NA                    | NA              | LR                      |
|                       |      | F/36    | Periaortic            | 21        | NA                    | NA              | Met to Sacrum            |
|                       |      | F/48    | Vertebral             | NA        | NA                    | NA              | Met to Lung              |
|                       |      | M/27    | Pulmonary vein        | NA        | NA                    | NA              | Met to Brain             |
|                       |      | F/14    | Ear                   | 30        | NA                    | NA              | NA                      |
|                       |      | F/55    | Hip                   | 4         | NA                    | NA              | NSR                     |
|                       |      | M/55    | Liver                 | 69        | NA                    | NA              | NSR                     |
|                       |      | M/15    | Foot                  | 12        | NA                    | NA              | NSR                     |
|                       |      | F/59    | Cheek                 | 95        | NA                    | NA              | NA                      |
|                       |      | M/9     | Finger                | NA        | NA                    | NA              | NA                      |
| Rokni et al[28]       | 2017 | F/78    | Forehead, eye         | 50        | 18 mo                 | Surgery; chemotherapy | NA                     |
| Sakamoto et al[29]    | 2017 | M/40    | Leg, foot             | 20–30     | 6 mo                  | Surgery; radiation | NSR after 2.5 yr         |
| Gok et al[30]         | 2020 | M/54    | Paraspinal region     | 26        | 2 yr                  | Surgery         | NSR after 1 yr           |
| Present case          | 2020 | M/65    | spleen                | 152       | NA                    | Partial excision| ADW after 6 mo          |

NA, not available; NSR, no sign of recurrence; LR, local recurrence; Met, metastasis. AWD, alive with disease.
affected limb can achieve better results.\textsuperscript{3,4} Other less common therapies, whether with or without resection, including radiotherapy and chemotheraphy, such as electron beam, interferon-alpha 2b, and thalidomide are also effective.\textsuperscript{10,25,28,29} According to the work of Sakamoto A et al, patients with multiple tumors of the foot and sole were treated with extensive resection and radiotherapy and was followed for 2.5 years through positron emission tomography with 2-deoxy-2-[fluorine-18] fluoro-D-glucose without recurrence or metastasis.\textsuperscript{29} However, some patients do not respond to chemotherapy. Patient with primary CHE of the spleen who had undergone splenectomy and two weeks of chemotherapy did not respond to chemotherapy and were subsequently given supportive treatment.\textsuperscript{7} In our case, the patient underwent splenectomy and was provided with the best supportive care afterward. After 6 months of follow-up, the patient is still alive. Common metastatic sites include liver, lung, brain, sacrum, and lymph nodes.\textsuperscript{13,17,14,19,21} The metastasis of CHE arising from the spleen seems to be more common than that from the superficial, which may be related to the blood flow of the spleen. Compared with previous reviews, patients in our report have a worse prognosis, with local recurrence, metastasis and local recurrence &metastasis accounting for 12, 8, and 8, respectively. The reason why the metastasis rate of this article is higher may be due to the inclusion of the latest study by Perry et al. Their research includes a subset of cases that behave aggressively and that express neuroendocrine marker, which expands the scope of CHE.\textsuperscript{14} The metastasis in this article is 36\%, which is much higher than that reported by Nayler et al.\textsuperscript{3} Based on the expression of neuroendocrine markers and the location of the onset, whether this subset is distinguished from “regular” CHE that behaves more inertly requires further learning.

5. Conclusion
The CHE of the spleen is an extremely rare vascular tumor, which is difficult to diagnose before surgery. Preoperative puncture to determine pathology is recommended when CT examination reveals splenic lobulated low-density mass with heterogeneous enhancement. Since the biological behavior is still uncertain, local excision is the first choice for treatment. In order to ensure the timely detection of recurrence and metastasis, strict follow-up is necessary.

Author contributions

Conceptualization: Pan Liang.
Supervision: Yan Xing Zhang, Yi Yang Liu.
Validation: Pan Liang.
Writing – original draft: Wei Wei Li.
Writing – review & editing: Hui Ping Zhao, Jian Bo Gao.

References

[1] Requena L, Kutzner H. Hemangioendothelioma. Semin Diagn Pathol 2013;30:32–44.
[2] Koch M, Nielsen GP, Yoon SS. Malignant tumors of blood vessels: angiosarcomas, hemangioendotheliomas, and hemangierocytomas. J Surg Oncol 2008;97:321–9.
[3] Nayler SJ, Rubin BP, Calonje E, Chan JK, Fletcher CD. Composite hemangioendothelioma: a complex, low-grade vascular lesion mimicking angiosarcoma. Am J Surg Pathol 2000;24:352–61.
[4] Reis-Filho JS, Paiva ME, Lopes JM. Congenital composite hemangioendothelioma: case report and reappraisal of the hemangioendothelioma spectrum. J Cutaneous Pathol 2002;29:226–31.
[5] Sapunar J, Roa JC, Moscoso S. Reversion of hypophosphatemia after the excision of a composite hemangiocendothelioma in the great toe. Rev Med Chile 2003;131:909–14.
[6] Fukunaga M, Suzuki K, Saegusa N, Folpe AL. Composite hemangioendothelioma: report of 5 cases including one with associated Maffucci syndrome. Am J Surg Pathol 2007;31:1567–72.
[7] Yoda Y, Ohashi M. A case of composite hemangioendothelioma arising from the spleen: Jap J Clin Oncol 2012;42:770.
[8] Stojisic Z, Brasanac D, Stojanovic M, Boricic M. Cutaneous composite hemangioendothelioma: case report and review of published reports. Ann Saudi Med 2014;34:182–8.
[9] Cobianchi L, Lucioni M, Rosso R, et al. Unique vascular tumor primary arising in the liver and exhibiting histopathological features consistent with so-called polymorphic hemangioendothelioma. Pathol Int 2009;59:890–4.
[10] Zhang J, Wu B, Zhou GQ, et al. Composite hemangioendothelioma arising from the kidney: case report with review of the literature. Int J Clin Exp Pathol 2013;6:1933–41.
[11] Tromanier M, Vogelbruch M, Kutzner H. Spindle cell hemangioma and epithelioid hemangioendothelioma arising in an area of lymphedema. Am J Dermatopathol 2006;28:223–7.
[12] Fasolis M, Iaquinta C, Montesco MC, et al. Composite hemangiendothelioma of the oral cavity: case report and review of the literature. Head Neck 2008;30:974–9.
[13] Bhat A, Chowdappa V. Composite hemangioendothelioma: report of a rare case. JCDR 2016;10:Ed01–Ed03.
[14] Perry KD, Al-Lbraheemi A, Rubin BP, et al. Composite hemangioendothelioma with neuroendocrine marker expression: an aggressive variant. Modern Pathol 2017;30:1598–602.
[15] Tejera-Vaquezio A, Herrera-Ceballos E, Bosch-García R, et al. Composite cutaneous hemangioendothelioma on the back. Am J Dermatopathol 2008;30:264–7.
[16] Cakir E, Demirag F, Gulhan E, et al. Mediastinal composite hemangioendothelioma. A rare tumor at an unusual location. Tumori 2009;95:98–100.
[17] Dong A, Bai Y, Wang Y, et al. Bone scan, MRI, and FDG PET/CT findings in composite hemangioendothelioma of the manubrium sterni. Clin Nucl Med 2014;39:e180–3.
[18] Biagioli M, Stano P, Miracco C, Fimiani M. Composite cutaneous haemangioendothelioma: case report and review of the literature. Clin Exp Dermatol 2005;30:385–7.
[19] Requena L, Lázaro Díaz J, Manzarbeitia F, et al. Composite cutaneous hemangioendothelioma on the back. Am J Dermatopathol 2008;30:264–7.
[20] Cakir E, Demirag F, Gulhan E, et al. Mediastinal composite hemangioendothelioma. A rare tumor at an unusual location. Tumori 2009;95:98–100.
[21] Aydingöz IE, Demirkesen C, Serdar ZA, Mansur AT, Yaşar S, Aslan C. Composite haemangioendothelioma: an unusual presentation at an uncommon site. Clin Exp Dermatol 2009;34:503–5.
[22] Tsai JW, Huang HY, Lee JC, et al. Composite haemangioendothelioma: report of four cases with emphasis on atypical clinical presentation. Pathology 2011;43:176–80.
[23] Chen YL, Chen WX, Wang J, et al. Composite hemangioendothelioma on the neck. Kaohsiung J Med Sci 2012;28:564–5.
[24] Liu JY, Lee FY, Chiu CS, et al. Composite hemangioendothelioma presenting as a scalp nodule with alopecia. J Am Acad Dermatol 2013;69:98–9.
[25] Tateshi J, Saeki H, Ito K, et al. Cutaneous composite hemangioendothelioma on the nose treated with electron beam. Int J Dermatol 2013;52:1618–9.
[26] Mahmoudzadeh R, Samrao A, Benton JJ, Peng SK, Bhatia N. Composite hemangioendothelioma: an unusual presentation of a rare vascular tumor. Am J Clin Pathol 2014;141:e73–6.
[27] Leen SL, Clarke PM, Chapman J, et al. Composite hemangioendothelioma of the submandibular region. Head Neck Pathol 2015;9:219–24.
[28] Rokni GR, Montazer F, Shariati M, et al. Composite hemangioendothelioma of the forehead and right eye; a case report. BMC Dermatol 2013;5:24.
[31] Bowerson M, Menias CO, Lee K, et al. Hot spleen: hypervascular lesions of the spleen. Abdom Imaging 2015;40:2796–813.

[32] Thompson WM, Levy AD, Aguilera NS, et al. Angiosarcoma of the spleen: imaging characteristics in 12 patients. Radiology 2005;235:106–15.

[33] Kaza RK, Azar S, Al-Hawary MM, et al. Primary and secondary neoplasms of the spleen. Cancer Imaging 2010;10:173–82.

[34] Robert M, Abbott ADL, Aguilera Nadine S, et al. Primary vascular neoplasms of the spleen: radiologic-pathologic correlation. Radiographics 2004;24:1137–63.